PL 14
Alternative Names: PL-14Latest Information Update: 29 Mar 2006
Price :
$50 *
At a glance
- Originator Debiopharm
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Endometriosis; Prostate cancer
Most Recent Events
- 29 Mar 2006 Preregistration for Endometriosis in Switzerland (unspecified route)
- 29 Mar 2006 Preregistration for Prostate cancer in Switzerland (unspecified route)
- 26 Aug 2005 Phase-III clinical trials in Endometriosis in Switzerland (unspecified route)